Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on May 15, 2018. The company is incorporated in Delaware and is designated as an emerging growth company. The report addresses a material modification to the rights of security holders regarding the company's Series Z warrants.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a corporate action regarding warrant exercise prices.
Material Changes
- Warrant Price Reduction: The Board of Directors approved a reduction in the exercise price of the Series Z Warrants (CUSIP: 70387R122, Symbol: PAVMZ).
- Price Adjustment: The exercise price was reduced from $3.00 per share to $1.60 per share.
- Effective Date: The reduction is scheduled to take effect on June 1, 2018, contingent upon notice being provided to current warrant holders.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or a discussion of general business risks. The primary contingency noted is the requirement to provide notice to current holders of Series Z Warrants before the price reduction becomes effective.
Investor Verification Checklist
- Verify the receipt of official notice regarding the warrant price reduction by current Series Z Warrant holders.
- Confirm the effective date of the price reduction (June 1, 2018) and the new exercise price ($1.60).
- Review the press release filed as Exhibit 99.1 for additional details on the rationale for the price adjustment.